Abstract Number: 1603 • 2016 ACR/ARHP Annual Meeting
Clinical Responses to Tocilizumab Analyzed By Serologic Status in Rheumatoid Arthritis
Clinical Responses to Tocilizumab Analyzed by Serologic Status in Rheumatoid Arthritis Background/Purpose: Biologic medications have improved outcomes for patients with rheumatoid arthritis (RA), but little…Abstract Number: 1636 • 2016 ACR/ARHP Annual Meeting
Decrease of Tocilizumab in Rheumatoid Arthritis in Remission : A Multicenter Study
Background/Purpose: The advent of biological therapies in rheumatoid arthritis has significantly reduced the activity of rheumatoid arthritis, leading to obtaining a remission in a significant…Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…Abstract Number: 1602 • 2015 ACR/ARHP Annual Meeting
Beta Cells Function and Insulin Resistance during Tocilizumab Treatment in Non-Diabetic RA Patients: Results from a Single-Center Study
Background/Purpose: Insulin resistance (IR) is increased and β-cell function impaired in rheumatoid arthritis (RA). The aim of this study was to evaluate whether treatment with…Abstract Number: 1651 • 2015 ACR/ARHP Annual Meeting
Comparison of Oral Glucocorticoid (OGC)-Sparing Effects in Tocilizumab and Other Biologic Dmards Using Multilevel Models in an Administrative Health Care Claims Database
Background/Purpose : The current treatment paradigm in rheumatoid arthritis (RA) is to attempt to decrease, when clinically feasible, concomitant use of OGCs after their use…Abstract Number: 1664 • 2015 ACR/ARHP Annual Meeting
Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.
Background/Purpose: Tocilizumab (TCZ) represents an efficacious alternative for patients with rheumatoid arthritis (RA) with an inadequate clinical response to biological or non-biological disease-modifying anrirheumatic drugs…Abstract Number: 2731 • 2015 ACR/ARHP Annual Meeting
Persistency of Tocilizumab As Monotherapy or Combination Therapy in Patients with Rheumatoid Arthritis–Real-World Analyses from the US Corrona Registry
Background/Purpose: For patients with rheumatoid arthritis (RA), there are limited real-world data on factors that predict persistency on biologic therapy or whether use of biologics…Abstract Number: 2753 • 2015 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab in Biologics-Naive RA Patients – Postmarketing Surveillance for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naive RA Patients (FIRST Bio) Study
Background/Purpose: The all-patient postmarketing surveillance (PMS) of tocilizumab (TCZ; PMS7901), which followed 7901 rheumatoid arthritis (RA) patients for 28 weeks (wks), showed that patients with…Abstract Number: 2756 • 2015 ACR/ARHP Annual Meeting
Impact of Tocilizumab Monotherapy on Patient-Reported Quality of Life Outcomes in the US Corrona Registry
Background/Purpose: The objective of this real-world analysis was to examine the impact of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) on patient-reported outcomes (PROs) in…Abstract Number: 2771 • 2015 ACR/ARHP Annual Meeting
Impact of Tocilizumab Monotherapy in Patients with Moderate to High Disease Activity: Real-World Analyses from the US Corrona Registry
Background/Purpose: Little is known regarding the real-world use and effectiveness of the interleukin-6 receptor α inhibitor tocilizumab (TCZ) as monotherapy. The effectiveness of TCZ monotherapy…Abstract Number: 2782 • 2015 ACR/ARHP Annual Meeting
Not Only 5 but Also 6 Weeks Intervals of Tocilizumab Infusion Induce Clinical Remission in Patients with Active Rheumatoid Arthritis
Background/Purpose: For active rheumatoid arthritis patients with inadequate response to synthetic disease modifying antirheumatic drugs (DMARDs), biologic agents are indicated. However, the cost of biologics,…Abstract Number: 496 • 2015 ACR/ARHP Annual Meeting
Increased Serum Lipids Under Tocilizumab Is Not Influenced By Methotrexate
Background/Purpose: Increased serum lipid levels in patients being treated with tocilizumab (TCZ) is known from several clinical trials1,2. It is not known whether additional methotrexate…Abstract Number: 499 • 2015 ACR/ARHP Annual Meeting
Efficacy of Tocilizumab Monotherapy in Patients with RA Is Not Influenced By ACPA Positivity
Background/Purpose: Rheumatoid arthritis (RA) patients with anti-citrullinated peptide antibodies (ACPA) need a more aggressive therapy (1). Tocilizumab (TCZ) seems to be the biologic with best…Abstract Number: 569 • 2015 ACR/ARHP Annual Meeting
Neurophil to Lymphocyte Ratio Is a Reliable Marker of Treatment Response in Rheumatoid Arthritis Patients during Tocilizumab Therapy
Background/Purpose: Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, is an effective drug for the treatment of rheumatoid arthritis (RA). During administration of tocilizumab, previous studies have…Abstract Number: 576 • 2015 ACR/ARHP Annual Meeting
Possibility of Extension of the Administration Interval of Tocilizumab in the Treatment of Rheumatoid Arthritis
Background/Purpose: Biologics constitute an important drug category in the pharmacological treatment of rheumatoid arthritis (RA). Drug-free remission (REM) may also be achievable if the condition…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 8
- Next Page »